Upper GI Therapy Device Makes Entry to Market
Mar 27 2020 Read 286 Times
Medical device company Medovate has secured the exclusive rights to bring to market a pioneering endoscopic surgical device, ENDOVAC, which has the potential to dramatically improve survival of patients with life threatening infection following a leak from the upper gastrointestinal (GI) tract.
Developed by a team led by Mr Andrew Hindmarsh, Consultant Oesophagogastric Surgeon at Cambridge University Hospitals NHS Foundation Trust, ENDOVAC is also backed by a £1.2m grant from the National Institute for Health Research, which has a number of regional specialist partners including the Hospital, the Cambridge Clinical Trials Unit, Health Enterprise East and Suffolk-based JEB Technologies Ltd. Medovate’s role is to attain regulatory approval and commercialise this technology, with a view to beginning clinical evaluation as early as 2021 and market launch thereafter.
Formerly treated by surgery, a more recent treatment strategy for this problem called Endoluminal Vacuum Therapy (EVT) still needs improvement as it requires multiple technically difficult procedures under general anaesthesia in an operating theatre to be successful.
ENDOVAC is a ground-breaking progression of EVT, delivering treatment without the need for general anaesthesia, providing a safer, quicker, easier and cheaper option. Importantly, it is far less traumatic for patients enabling mobility during treatment, unlike standard EVT, where patients are often confined to their hospital beds.
Robert Donald, New Business Manager at Medovate, said: “ENDOVAC offers a deceptively simple solution to a complex problem that has sadly claimed many lives over the years. The team at Cambridge University Hospitals NHS Foundation Trust have come up with a straightforward yet effective device that presents a compelling proposition in terms of both patient outcomes and potentially significant cost-savings to the NHS.
“ENDOVAC is a natural addition to the Medovate portfolio of innovations in the fields of surgery, anaesthesia and intensive care. We are excited to be working with Mr Andrew Hindmarsh and his colleagues to bring such a ground-breaking product to market, and we fully expect to see ENDOVAC in use in our hospitals in the not-too-distant future.”
Do you like or dislike what you have read? Why not post a comment to tell others / the manufacturer and our Editor what you think. To leave comments please complete the form below. Providing the content is approved, your comment will be on screen in less than 24 hours. Leaving comments on product information and articles can assist with future editorial and article content. Post questions, thoughts or simply whether you like the content.
In This Edition Articles - Export experts talk Corona Virus - Automated cell counting shouldn’t cost the earth Laboratory Products - Spectrophotometer Linearity Validation - Analysi...
View all digital editions
May 31 2020 Houston, TX, USA
May 31 2020 Baltimore, MD, USA
Jun 11 2020 Brussels, Belgium
Jun 20 2020 San Diego, CA, USA
Jun 30 2020 Nuremberg, Germany